Oncology & Cancer

EU approves treatment for prostate cancer

The European Union has approved a new treatment against an advanced type of prostate cancer by Novartis, the Swiss pharmaceutical giant said Tuesday.

Medications

Novartis, Roche team up on COVID pneumonia drug

Novartis announced Thursday it will join forces with fellow Swiss pharmaceutical giant Roche to produce tocilizumab, a drug being tested for its effectiveness against COVID-19-linked pneumonia.

Medications

Novartis to pay $336 mn in US settlements on bribes

Novartis agreed to pay around $336 million to settle US charges connected to bribery schemes aimed at increasing sales of its pharmaceutical products, US authorities announced Thursday.

Oncology & Cancer

FDA approves CAR T therapy for large B-cell lymphoma

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...

page 1 from 16

Novartis

Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number one in revenues, which accounted over $53 billion in 2008, and number three in sales, which accounted 36.172 billon in 2008 . Novartis is one of the largest healthcare companies in the world and a leading giant among pharmaceutical companies. Novartis manufactures drugs such as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), cyclosporin A (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Novartis owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.

Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

This text uses material from Wikipedia, licensed under CC BY-SA